Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/65898
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Therapies for neurological disease in the mucopolysaccharidoses |
Author: | Anson, D. McIntyre, C. Byers, S. |
Citation: | Current Gene Therapy: the international journal for in-depth reviews on gene therapy, 2011; 11(2):132-143 |
Publisher: | Bentham Science Publishers Ltd. |
Issue Date: | 2011 |
ISSN: | 1566-5232 1875-5631 |
Statement of Responsibility: | Donald S. Anson, Chantelle McIntyre, Sharon Byers |
Abstract: | Intravenous enzyme replacement therapy has been developed as a viable treatment for most of the somatic pathologies associated with the mucopolysaccharide storage disorders. However, approximately two thirds of individuals affected by a mucopolysaccharide storage disorder also display neurological disease, in these instances intravenous enzyme replacement therapy is not viable as the blood-brain barrier severely limits enzyme distribution from the peripheral circulation into the central nervous system. Accordingly, much research is now focussed on developing therapies that specifically address neurological disease, or somatic and neurological disease in combination. Therapies designed to address the underlying cause of central nervous system pathology, that is the lysosomal storage itself, can be broadly divided into two groups, those that continue the rationale of enzyme replacement, and those that address the supply side of the storage equation; that is the production of storage material. Enzyme replacement can be further divided by technology (principally direct enzyme replacement, gene replacement and cell transplantation). Here we review the current state of the art for these strategies and suggest possible future directions for research in this field. In particular, we suggest that any one approach in itself is unlikely to be as efficacious as a carefully considered combination therapy, be it a combination of some sort of enzyme replacement with substrate deprivation, or a combination of two different replacement technologies or strategies. |
Keywords: | Disease glycosaminoglycan mucopolysaccharidosis neurological storage therapy Enzyme replacement CNS pathology Blood-Brain Barrier AAV vector ependyma |
Rights: | Copyright status unknown |
DOI: | 10.2174/156652311794940791 |
Published version: | http://proxy.library.adelaide.edu.au/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=62092186&site=ehost-live&scope=site |
Appears in Collections: | Aurora harvest 5 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.